bio-techne[®] RDSYSTEMS

Human Podocalyxin Biotinylated Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: BAF1658

sections of human kidney

DESCRIPTION	
Species Reactivity	Human
Specificity	Detects human Podocalyxin in Western blots.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Podocalyxin Ser23-Arg427 Accession # AAB61574
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.				
	Recommended Concentration	Sample		
Western Blot	0.1 µg/mL	Recombinant Human Podocalyxin		
Immunohistochemistry	5-15 μg/mL	Immersion fixed paraffin-embedded		

PREPARATION AND STORAGE			
Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.		
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.		
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.		
	 12 months from date of receipt, -20 to -70 °C as supplied. 		
	 1 month, 2 to 8 °C under sterile conditions after reconstitution. 		
	 6 months, -20 to -70 °C under sterile conditions after reconstitution. 		

BACKGROUND

Podocalyxin, also known as Podocalyxin-like protein-1 (PCLP1 or PODXL), is a type I transmembrane glycoprotein. It belongs to the CD34/Podocalyxin family of sialomucins that share structural similarity and sequence homology. Podocalyxin is a major sialoprotein in the podocytes of the kidney glomerulus and is also expressed by both endothelium and multipotent hematopoietic progenitors. It has been identified as a novel cell surface marker for hemangioblasts, the common precursors of hematopoietic and endothelial cells (1, 2).

References:

- 1. Li, J. et al. (2001) DNA Seq. 12:407.
- 2. Hara, T. et al. (1999) Immunity 11:567.

Rev. 6/20/2025 Page 1 of 1